Lucid Diagnostics is a commercial-stage medical diagnostics technology company focused on patients with gastroesophageal reflux (GERD) disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). Co.'s lead products, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell Collection Device in a noninvasive office procedure, serving as a screening tool to prevent EAC deaths, through early detection of esophageal precancer and cancer in at-risk GERD patients. The LUCD average annual return since 2021 is shown above.
The Average Annual Return on the LUCD average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether LUCD average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LUCD average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|